TP53BP1 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant TP53BP1.
- 产品详情
- 实验流程
Application
| E |
|---|---|
| Primary Accession | Q12888 |
| Other Accession | NM_005657 |
| Reactivity | Human |
| Host | mouse |
| Clonality | monoclonal |
| Isotype | IgG1 Kappa |
| Clone Names | 1B9 |
| Calculated MW | 213574 Da |
| Gene ID | 7158 |
|---|---|
| Other Names | Tumor suppressor p53-binding protein 1, 53BP1, p53-binding protein 1, p53BP1, TP53BP1 |
| Target/Specificity | TP53BP1 (NP_005648, 1766 a.a. ~ 1874 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | E~~N/A |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | TP53BP1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
REFERENCES
Genetic Variants in the 53BP1 Gene and Skin Cancer Risk. He C, et al. J Invest Dermatol, 2010 Aug 5. PMID 20686496.Evaluation of Single Nucleotide Polymorphisms (SNPs) in the p53 Binding Protein 1 (TP53BP1) Gene in Breast Cancer Patients Treated With Breast-Conserving Surgery and Whole-Breast Irradiation (BCS + RT). Haffty BG, et al. Int J Radiat Oncol Biol Phys, 2010 Jun 18. PMID 20646866.A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Ho-Pun-Cheung A, et al. Pharmacogenomics J, 2010 Jul 20. PMID 20644561.53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Bouwman P, et al. Nat Struct Mol Biol, 2010 Jun. PMID 20453858.A Large-scale genetic association study of esophageal adenocarcinoma risk. Liu CY, et al. Carcinogenesis, 2010 Jul. PMID 20453000.
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。